» Articles » PMID: 1719465

Expression of the Met/HGF Receptor in Normal and Neoplastic Human Tissues

Overview
Journal Oncogene
Date 1991 Nov 1
PMID 1719465
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

The MET oncogene encodes a transmembrane tyrosine kinase receptor. Recently, hepatocyte growth factor (HGF), a potent growth factor for hepatocytes involved in liver regeneration, has been proposed as a ligand. In this paper, the physiological role of the human Met/HGF receptor is investigated by studying its specific distribution in normal and neoplastic tissues. Northern blot analysis has shown that the MET gene is selectively expressed in several epithelial tissues. High levels of MET mRNA have been found in liver, gastrointestinal tract, thyroid and kidney. Western blot analysis has shown that the levels of the Met protein generally correspond to those of the mRNA. However, in the thyroid, where there is a high level of MET mRNA, the protein was barely detectable, suggesting translational or post-translational regulation. The protein was also detected in the brain. Normal or increased levels of MET mRNA and Met protein were consistently found in fresh samples of carcinomas as well as in epithelial tumor cell lines. In thyroid carcinomas of a specific histiotype the amount of Met protein, almost undetectable in the normal counterpart, was found to be increased more than 100-fold. The tissue distribution of the Met/HGF receptor indicates that this molecule is involved in growth control of epithelial cells other than hepatocytes and suggests that its increased expression may confer a growth advantage to neoplastic cells.

Citing Articles

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.


Cancer cell targeting by CAR-T cells: A matter of stemness.

DAccardo C, Porcelli G, Mangiapane L, Modica C, Pantina V, Roozafzay N Front Mol Med. 2024; 2:1055028.

PMID: 39086964 PMC: 11285689. DOI: 10.3389/fmmed.2022.1055028.


MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.

Spitaleri G, Trillo Aliaga P, Attili I, Del Signore E, Corvaja C, Corti C Cancers (Basel). 2023; 15(19).

PMID: 37835473 PMC: 10571577. DOI: 10.3390/cancers15194779.


Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges.

Su P, Zhang M, Kang X Front Oncol. 2023; 13:1071030.

PMID: 36959792 PMC: 10028134. DOI: 10.3389/fonc.2023.1071030.


Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions.

Marcantonio D, Matteson A, Presler M, Burke J, Hagen D, Hua F Front Pharmacol. 2022; 13:864768.

PMID: 35754500 PMC: 9214263. DOI: 10.3389/fphar.2022.864768.